Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, the body’s immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibres. This is often characterized by the relapse of neurologic impairment, followed by remissions. The damaged myelin forms scar tissue (sclerosis). Often the nerve fibre is also damaged. When any part of the myelin sheath or nerve fibre is damaged or destroyed, nerve impulses travelling to and from the brain and spinal cord are distorted or interrupted.

According to the revised McDonald Criteria, Multiple Sclerosis Relapse is defined as a “patient-reported or objectively observed event typical of an acute inflammatory demyelinating event in the central nervous system, current or historical, with the duration of at least 24 hours in the absence of fever or infection.”

Spasticity, one of MS’s most common symptoms, causes muscles to feel stiff and heavy, making movement difficult. An estimated 60–90% of people with MS experience spasticity at some point.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/multiple-sclerosis-market

The Multiple Sclerosis market report also covers emerging drugs, current treatment practices, Multiple Sclerosis market share of the individual therapies, current and forecasted Multiple Sclerosis Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Multiple Sclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Multiple Sclerosis Market Key Facts

• According to the study published by Leray et al., Multiple sclerosis (MS) is the most common demyelinating disease seen in high-income countries and has a heterogeneous prevalence worldwide it is highest in North America (140/100,000 population) and Europe (108/100,000), and lowest in East Asia (2.2/100,000 population) and sub-Saharan Africa (2.1/100,000).

• Assessments by DelveInsight’s analysts reveal a higher prevalence of Multiple Sclerosis in the United States.

• Among the European five countries, Germany had the highest prevalent population of Multiple Sclerosis, followed by France. On the other hand, Spain had the lowest prevalent population in 2017. Japan had the lowest prevalent population of Multiple Sclerosis.

• As per DelveInsight’s estimates, maximum MS people had relapsing-remitting MS followed by primary progressive MS.

Key Benefits of Multiple Sclerosis Market Report

• Multiple Sclerosis market report provides an in-depth analysis of Multiple Sclerosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

• The Multiple Sclerosis market report will help in developing business strategies by understanding the Multiple Sclerosis Market trends & developments, key players, and future market competition that will shape and drive the Multiple Sclerosis market in the upcoming years.

• The Multiple Sclerosis market report covers Multiple Sclerosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

• The report provides a detailed assessment of the Multiple Sclerosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Multiple Sclerosis Market

The Multiple Sclerosis market size shall increase during the forecast period owing to the launch of upcoming therapies, increasing healthcare expenditure, rise in R&D activities, and awareness among patients about the treatment options.

The Multiple Sclerosis market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Multiple Sclerosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Multiple Sclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Multiple Sclerosis Epidemiology

The Multiple Sclerosis epidemiology sections cover insights about the historical and current Multiple Sclerosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Multiple Sclerosis Epidemiology Segmentation – 

• Prevalent Population of Multiple Sclerosis

• Sex-Specific Prevalence of Multiple Sclerosis

• Sub-type Specific Prevalence of Multiple Sclerosis

• Age-Specific Prevalence of Multiple Sclerosis

• Prevalence of Multiple Sclerosis based on EDSS Score

Multiple Sclerosis Drugs Uptake and Key Market Players

The Multiple Sclerosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched in the market during the study period. The analysis covers Multiple Sclerosis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple Sclerosis Companies:
AB Science
Merck
Novartis
Biogen Idec
Brainstorm
Genentech
Genzyme
Acorda Therapeutics
Adamas Pharmaceuticals
Bayer Healthcare
Celgene Corporation
Clene Nanomedicine
Johnson & Johnson
MedDay Pharma
Teva Pharmaceutical
TG Therapeutics
And many others.

Multiple Sclerosis Therapies covered in the report include:
Lemtrada
Zinbryta
Ocrevus
Mavenclad
Mayzent
ALKS 8700
NVG-291
Ublituximab
Ozanimod
NurOwn
MD1003
Masitinib
Ponesimod
Evobrutinib
ADS-5102
CNM-Au8
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Epidemiology and Patient Population

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Products

12. Multiple Sclerosis Emerging Therapies

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (7 major markets)

16. Multiple Sclerosis Access and Reimbursement Overview

17. KOL Views on the Multiple Sclerosis Market.

18. Multiple Sclerosis Market Drivers

19. Multiple Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Latest Reports By DelveInsight
Multiple Sclerosis Pipeline Insights
Multiple Sclerosis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Multiple Sclerosis market.

Cardiac Biomarkers Testing Devices Market
DelveInsight’s ‘Cardiac Biomarkers Testing Devices Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Cardiac Biomarkers Testing Devices and the historical and forecasted Cardiac Biomarkers Testing Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/